Dosing Interval Extension of Dupilumab in CRSwNP: Five-Year Real World Outcomes - PubMed

4 hours ago

Dupilumab shows significant long-term benefits for CRSwNP patients, with sustained improvements in polyp burden, olfactory function, and quality of life over 5 years.
40% of patients extended dosing intervals after achieving stable disease control without losing efficacy, and reported fewer treatment-related adverse events.
Common side effects included musculoskeletal complaints, skin reactions, and injection site reactions, with an overall incidence of 16%.
Personalized dosing-interval extension is a viable strategy to reduce treatment burden and maintain efficacy, especially for patients with troublesome side effects.
The study supports the durability and safety of long-term dupilumab therapy in CRSwNP management.

Hasty Briefsbeta